Piper Jaffray is out with its report today on Gen-Probe GPRO, raising its PT from $69 to $78.
In a note to clients, Piper Jaffray writes, "Our quarterly checks suggest improving CT/NG testing volumes, with surveyed accounts describing a 2.2% sequential volume increase. For comparative purposes, we include preliminary CDC data which show yoy growth in reported cases of CT/NG. These channel checks give us increased confidence in our above-consensus 1Q11 revenue estimate ($143.4M vs. Street: $141.2M). We are adjusting our EPS expectations (modestly lower gross margin and higher opex), although our estimate remains above consensus ($0.55 vs. Street: $0.52). We reiterate our Overweight and raise our price target to $78."
Shares of GPRO closed Thursday at $68.82, up 1.04% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst Ratingsgen-probeHealth CareHealth Care EquipmentPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in